206 related articles for article (PubMed ID: 31976522)
1. DMD carrier model with mosaic dystrophin expression in the heart reveals complex vulnerability to myocardial injury.
Meyers TA; Heitzman JA; Townsend D
Hum Mol Genet; 2020 Apr; 29(6):944-954. PubMed ID: 31976522
[TBL] [Abstract][Full Text] [Related]
2. Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.
Wasala NB; Bostick B; Yue Y; Duan D
Hum Mol Genet; 2013 Jul; 22(13):2634-41. PubMed ID: 23459935
[TBL] [Abstract][Full Text] [Related]
3. Acute AT
Meyers TA; Heitzman JA; Krebsbach AM; Aufdembrink LM; Hughes R; Bartolomucci A; Townsend D
J Mol Cell Cardiol; 2019 Mar; 128():51-61. PubMed ID: 30664850
[TBL] [Abstract][Full Text] [Related]
4. Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.
Betts CA; Saleh AF; Carr CA; Hammond SM; Coenen-Stass AM; Godfrey C; McClorey G; Varela MA; Roberts TC; Clarke K; Gait MJ; Wood MJ
Sci Rep; 2015 Mar; 5():8986. PubMed ID: 25758104
[TBL] [Abstract][Full Text] [Related]
5. Enhanced dimethylarginine degradation improves coronary flow reserve and exercise tolerance in Duchenne muscular dystrophy carrier mice.
Garbincius JF; Merz LE; Cuttitta AJ; Bayne KV; Schrade S; Armstead EA; Converso-Baran KL; Whitesall SE; D'Alecy LG; Michele DE
Am J Physiol Heart Circ Physiol; 2020 Sep; 319(3):H582-H603. PubMed ID: 32762558
[TBL] [Abstract][Full Text] [Related]
6. Uniform low-level dystrophin expression in the heart partially preserved cardiac function in an aged mouse model of Duchenne cardiomyopathy.
Wasala NB; Yue Y; Vance J; Duan D
J Mol Cell Cardiol; 2017 Jan; 102():45-52. PubMed ID: 27908661
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis of dystrophin deficiency and associated changes in the aged mdx-4cv heart model of dystrophinopathy-related cardiomyopathy.
Murphy S; Dowling P; Zweyer M; Mundegar RR; Henry M; Meleady P; Swandulla D; Ohlendieck K
J Proteomics; 2016 Aug; 145():24-36. PubMed ID: 26961938
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.
Siemionow M; Malik M; Langa P; Cwykiel J; Brodowska S; Heydemann A
Stem Cell Rev Rep; 2019 Dec; 15(6):827-841. PubMed ID: 31612351
[TBL] [Abstract][Full Text] [Related]
9. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.
Jearawiriyapaisarn N; Moulton HM; Sazani P; Kole R; Willis MS
Cardiovasc Res; 2010 Feb; 85(3):444-53. PubMed ID: 19815563
[TBL] [Abstract][Full Text] [Related]
10. Exosome-Derived Dystrophin from Allograft Myogenic Progenitors Improves Cardiac Function in Duchenne Muscular Dystrophic Mice.
Su X; Jin Y; Shen Y; Ju C; Cai J; Liu Y; Kim IM; Wang Y; Yu H; Weintraub NL; Jiang M; Tang Y
J Cardiovasc Transl Res; 2018 Oct; 11(5):412-419. PubMed ID: 30155598
[TBL] [Abstract][Full Text] [Related]
11. Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice.
Yue Y; Skimming JW; Liu M; Strawn T; Duan D
Hum Mol Genet; 2004 Aug; 13(15):1669-75. PubMed ID: 15190010
[TBL] [Abstract][Full Text] [Related]
12. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy.
Bostick B; Shin JH; Yue Y; Wasala NB; Lai Y; Duan D
J Mol Cell Cardiol; 2012 Aug; 53(2):217-22. PubMed ID: 22587991
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular phenotype of the
Szabó PL; Ebner J; Koenig X; Hamza O; Watzinger S; Trojanek S; Abraham D; Todt H; Kubista H; Schicker K; Remy S; Anegon I; Kiss A; Podesser BK; Hilber K
Dis Model Mech; 2021 Feb; 14(2):. PubMed ID: 33619211
[TBL] [Abstract][Full Text] [Related]
14. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart.
Yue Y; Li Z; Harper SQ; Davisson RL; Chamberlain JS; Duan D
Circulation; 2003 Sep; 108(13):1626-32. PubMed ID: 12952841
[TBL] [Abstract][Full Text] [Related]
15. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
16. Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model.
Howard ZM; Dorn LE; Lowe J; Gertzen MD; Ciccone P; Rastogi N; Odom GL; Accornero F; Chamberlain JS; Rafael-Fortney JA
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33651713
[TBL] [Abstract][Full Text] [Related]
17. The multifaceted view of heart problem in Duchenne muscular dystrophy.
Florczyk-Soluch U; Polak K; Dulak J
Cell Mol Life Sci; 2021 Jul; 78(14):5447-5468. PubMed ID: 34091693
[TBL] [Abstract][Full Text] [Related]
18. Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity.
Malerba A; Boldrin L; Dickson G
Nucleic Acid Ther; 2011 Aug; 21(4):293-8. PubMed ID: 21851223
[TBL] [Abstract][Full Text] [Related]
19. Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.
Spurney CF; Guerron AD; Yu Q; Sali A; van der Meulen JH; Hoffman EP; Nagaraju K
BMC Cardiovasc Disord; 2011 May; 11():20. PubMed ID: 21575230
[TBL] [Abstract][Full Text] [Related]
20. Dystrophin Deficiency Causes Progressive Depletion of Cardiovascular Progenitor Cells in the Heart.
Jelinkova S; Sleiman Y; Fojtík P; Aimond F; Finan A; Hugon G; Scheuermann V; Beckerová D; Cazorla O; Vincenti M; Amedro P; Richard S; Jaros J; Dvorak P; Lacampagne A; Carnac G; Rotrekl V; Meli AC
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34068508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
